Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Ferring invests $15m in Israeli unit Bio-Technology General
#Investment
About
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing, and marketing products in the fields of reproductive health, urology, gastroenterology, endocrinology, and orthopedics. The company's research activities and products are connected by a common focus of providing tailored treatments that work on the body's own terms, enabling doctors to combat numerous diseases and medical conditions.
With the acquisition of the Israeli company Bio-Technology General (BTG) in 2005, Ferring gained capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing. There are two Ferring sites in Israel: Ferring Pharmaceuticals Israel, a manufacturing and distribution site, and Bio-Technology General, which is involved in the development of recombinant biologics and biotechnology, as well as manufacturing. Ferring and BTG actively search for in-licensing opportunities and product acquisitions in Ferring's key areas of therapeutic activity, reproductive health, endocrinology, urology, gastroenterology, and orthopedics.